{"id":791491,"date":"2024-12-02T08:18:38","date_gmt":"2024-12-02T13:18:38","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/hepion-pharmaceuticals-issues-letter-to-shareholders-urging-support-for-proposed-merger-with-pharma-two-b\/"},"modified":"2024-12-02T08:18:38","modified_gmt":"2024-12-02T13:18:38","slug":"hepion-pharmaceuticals-issues-letter-to-shareholders-urging-support-for-proposed-merger-with-pharma-two-b","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/hepion-pharmaceuticals-issues-letter-to-shareholders-urging-support-for-proposed-merger-with-pharma-two-b\/","title":{"rendered":"Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B"},"content":{"rendered":"
\n

\n Transaction Creates Opportunity to Share in Potential Upside of Pharma Two B\u2019s Late-Clinical Stage Candidate to Treat Parkinson\u2019s Disease<\/em>\n <\/p>\n

\n Hepion\u2019s Board Unanimously Recommends Shareholders Approve the Merger Following Review of Strategic Alternatives \u2013 Including Challenges of Remaining a Stand-Alone Company<\/em>\n <\/p>\n

\n EDISON, NJ, Dec. 02, 2024 (GLOBE NEWSWIRE) — <\/strong>Hepion Pharmaceuticals, Inc. (Nasdaq: HEPA) (\u201cHepion\u201d or the \u201cCompany\u201d), today sent an open letter to shareholders urging them to vote for Hepion\u2019s proposed merger with Pharma Two B Ltd. (\u201cPharma Two B\u201d) at the Company\u2019s upcoming Special Meeting of Stockholders (the \u201cSpecial Meeting\u201d) on December 12, 2024.<\/p>\n

The full text of the letter is below:<\/p>\n

December 2, 2024<\/p>\n

Dear Shareholders of Hepion Pharmaceuticals,<\/p>\n

We are writing to encourage your support for Hepion\u2019s proposed merger with Pharma Two B, which, we believe, best positions the Company\u2019s shareholders to maximize the value of their investment. Since the Company\u2019s formation over a decade ago, Hepion has worked on developing new drugs aimed at addressing critical diseases with the goal of improving the lives of a significant patient population. Regrettably, these efforts have not yielded the desired results and, after conducting a thorough review of strategic alternatives, Hepion\u2019s board of directors concluded a merger with Pharma Two B is in the best interests of all shareholders. We therefore urge you to\u00a0VOTE FOR<\/strong> this transformational transaction.<\/p>\n

As outlined in Hepion\u2019s definitive proxy statement dated November 8, 2024 (see link: Hepion Proxy Statement 2024 Special Meeting<\/a>), the continued clinical development of the Company\u2019s drug pipeline has become increasingly challenging due to numerous risk factors- including Hepion\u2019s inability to continue funding such development and the investment community\u2019s waning appetite for follow-on financing given the deteriorating risk profile. Quite simply, the Company lacked the financial resources to advance its clinical trials and the capital markets reflected no interest in funding further development of Hepion\u2019s pipeline on acceptable terms.<\/p>\n

Fortunately, the Company\u2019s review of strategic alternatives yielded a compelling opportunity to merge with Pharma Two B, a late-clinical stage biotechnology company developing an innovative treatment for Parkinson\u2019s Disease. Upon consummation of the proposed merger, Hepion\u2019s shareholders will be able to participate in the potential upside of Pharma Two B\u2019s promising product candidate known as P2B001.<\/p>\n

Furthermore, while Pharma Two B has indicated it has no plans to advance the clinical development of Hepion\u2019s legacy drug pipeline, Hepion remains committed to monetizing its value for the benefit of all shareholders. Although its efforts to date have not yielded any formal indications of interest, any such monetization could potentially provide further upside beyond Pharma Two B\u2019s compelling prospects. Of course, there can be no guaranty of the magnitude and timing of any potential sale, if at all.<\/p>\n

In the event Hepion\u2019s proposed merger with Pharma Two B does not receive the required shareholder support, the Company faces potentially dire consequences due to its limited financial resources. A stand-alone Hepion would be unable to fund the continued development of its legacy drug pipeline and would likely face delisting of its common stock from Nasdaq and potential bankruptcy. Any adjournment to solicit additional shareholder support could erode precious financial resources.<\/p>\n

Clearly, there is a better path forward for Hepion\u2019s shareholders. Pharma Two B presents an opportunity to share in the potential upside of its innovative drug candidate to treat Parkinson\u2019s Disease. P2B001\u2019s development is already more advanced than any candidates in Hepion\u2019s legacy pipeline and the post-merger company is expected to be well-funded to advance continued clinical trials with filing of a New Drug Application with the FDA on the horizon.<\/p>\n

We therefore strongly urge you to VOTE FOR<\/strong> Hepion\u2019s proposed merger with Pharma Two B. Please vote today to approve this important transaction. EVERY VOTE COUNTS! No matter how many shares you may own, the outcome of the special meeting may have a material impact on the value of your investment.<\/em><\/strong><\/p>\n

\n If you have any questions regarding the Special Meeting or need assistance voting, please contact Hepion\u2019s proxy solicitation firm Campaign Management, LLC toll-free at 1-855-422-1042 or via email at <\/strong>
\n
\n info@campaign-mgmt.com<\/strong>
\n <\/a> If you have already voted for Hepion\u2019s proposed merger with Pharma Two B, thank you for your support. If you have previously cast your vote against the merger, you can still change your vote at any time prior to the Special Meeting as only your latest dated vote will count.<\/p>\n

Sincerely,<\/p>\n

Hepion Pharmaceuticals, Inc.<\/p>\n

\n Contacts<\/strong>\n <\/p>\n

Investors:
Michael Fein
Campaign Management
(212) 632-8422
michael.fein@campaign-mgmt.com<\/u><\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Transaction Creates Opportunity to Share in Potential Upside of Pharma Two B\u2019s Late-Clinical Stage Candidate to Treat Parkinson\u2019s Disease Hepion\u2019s Board Unanimously Recommends Shareholders Approve the Merger Following Review of Strategic Alternatives \u2013 Including Challenges of Remaining a Stand-Alone Company EDISON, NJ, Dec. 02, 2024 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (Nasdaq: HEPA) (\u201cHepion\u201d or the \u201cCompany\u201d), today sent an open letter to shareholders urging them to vote for Hepion\u2019s proposed merger with Pharma Two B Ltd. (\u201cPharma Two B\u201d) at the Company\u2019s upcoming Special Meeting of Stockholders (the \u201cSpecial Meeting\u201d) on December 12, 2024. The full text of the letter is below: December 2, 2024 Dear Shareholders of Hepion Pharmaceuticals, We are writing to encourage your support for Hepion\u2019s … <\/p>\n

Continue reading “Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-791491","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nHepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/hepion-pharmaceuticals-issues-letter-to-shareholders-urging-support-for-proposed-merger-with-pharma-two-b\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Transaction Creates Opportunity to Share in Potential Upside of Pharma Two B\u2019s Late-Clinical Stage Candidate to Treat Parkinson\u2019s Disease Hepion\u2019s Board Unanimously Recommends Shareholders Approve the Merger Following Review of Strategic Alternatives \u2013 Including Challenges of Remaining a Stand-Alone Company EDISON, NJ, Dec. 02, 2024 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (Nasdaq: HEPA) (\u201cHepion\u201d or the \u201cCompany\u201d), today sent an open letter to shareholders urging them to vote for Hepion\u2019s proposed merger with Pharma Two B Ltd. (\u201cPharma Two B\u201d) at the Company\u2019s upcoming Special Meeting of Stockholders (the \u201cSpecial Meeting\u201d) on December 12, 2024. The full text of the letter is below: December 2, 2024 Dear Shareholders of Hepion Pharmaceuticals, We are writing to encourage your support for Hepion\u2019s … Continue reading "Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/hepion-pharmaceuticals-issues-letter-to-shareholders-urging-support-for-proposed-merger-with-pharma-two-b\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-02T13:18:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI5MTA4MiM2NjEzOTkxIzUwMDEyMDY2Ng==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hepion-pharmaceuticals-issues-letter-to-shareholders-urging-support-for-proposed-merger-with-pharma-two-b\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hepion-pharmaceuticals-issues-letter-to-shareholders-urging-support-for-proposed-merger-with-pharma-two-b\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B\",\"datePublished\":\"2024-12-02T13:18:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hepion-pharmaceuticals-issues-letter-to-shareholders-urging-support-for-proposed-merger-with-pharma-two-b\\\/\"},\"wordCount\":771,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hepion-pharmaceuticals-issues-letter-to-shareholders-urging-support-for-proposed-merger-with-pharma-two-b\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTI5MTA4MiM2NjEzOTkxIzUwMDEyMDY2Ng==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hepion-pharmaceuticals-issues-letter-to-shareholders-urging-support-for-proposed-merger-with-pharma-two-b\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hepion-pharmaceuticals-issues-letter-to-shareholders-urging-support-for-proposed-merger-with-pharma-two-b\\\/\",\"name\":\"Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hepion-pharmaceuticals-issues-letter-to-shareholders-urging-support-for-proposed-merger-with-pharma-two-b\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hepion-pharmaceuticals-issues-letter-to-shareholders-urging-support-for-proposed-merger-with-pharma-two-b\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTI5MTA4MiM2NjEzOTkxIzUwMDEyMDY2Ng==\",\"datePublished\":\"2024-12-02T13:18:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hepion-pharmaceuticals-issues-letter-to-shareholders-urging-support-for-proposed-merger-with-pharma-two-b\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hepion-pharmaceuticals-issues-letter-to-shareholders-urging-support-for-proposed-merger-with-pharma-two-b\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hepion-pharmaceuticals-issues-letter-to-shareholders-urging-support-for-proposed-merger-with-pharma-two-b\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTI5MTA4MiM2NjEzOTkxIzUwMDEyMDY2Ng==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTI5MTA4MiM2NjEzOTkxIzUwMDEyMDY2Ng==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hepion-pharmaceuticals-issues-letter-to-shareholders-urging-support-for-proposed-merger-with-pharma-two-b\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/hepion-pharmaceuticals-issues-letter-to-shareholders-urging-support-for-proposed-merger-with-pharma-two-b\/","og_locale":"en_US","og_type":"article","og_title":"Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B - Market Newsdesk","og_description":"Transaction Creates Opportunity to Share in Potential Upside of Pharma Two B\u2019s Late-Clinical Stage Candidate to Treat Parkinson\u2019s Disease Hepion\u2019s Board Unanimously Recommends Shareholders Approve the Merger Following Review of Strategic Alternatives \u2013 Including Challenges of Remaining a Stand-Alone Company EDISON, NJ, Dec. 02, 2024 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (Nasdaq: HEPA) (\u201cHepion\u201d or the \u201cCompany\u201d), today sent an open letter to shareholders urging them to vote for Hepion\u2019s proposed merger with Pharma Two B Ltd. (\u201cPharma Two B\u201d) at the Company\u2019s upcoming Special Meeting of Stockholders (the \u201cSpecial Meeting\u201d) on December 12, 2024. The full text of the letter is below: December 2, 2024 Dear Shareholders of Hepion Pharmaceuticals, We are writing to encourage your support for Hepion\u2019s … Continue reading \"Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/hepion-pharmaceuticals-issues-letter-to-shareholders-urging-support-for-proposed-merger-with-pharma-two-b\/","og_site_name":"Market Newsdesk","article_published_time":"2024-12-02T13:18:38+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI5MTA4MiM2NjEzOTkxIzUwMDEyMDY2Ng==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hepion-pharmaceuticals-issues-letter-to-shareholders-urging-support-for-proposed-merger-with-pharma-two-b\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hepion-pharmaceuticals-issues-letter-to-shareholders-urging-support-for-proposed-merger-with-pharma-two-b\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B","datePublished":"2024-12-02T13:18:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hepion-pharmaceuticals-issues-letter-to-shareholders-urging-support-for-proposed-merger-with-pharma-two-b\/"},"wordCount":771,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hepion-pharmaceuticals-issues-letter-to-shareholders-urging-support-for-proposed-merger-with-pharma-two-b\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI5MTA4MiM2NjEzOTkxIzUwMDEyMDY2Ng==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hepion-pharmaceuticals-issues-letter-to-shareholders-urging-support-for-proposed-merger-with-pharma-two-b\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/hepion-pharmaceuticals-issues-letter-to-shareholders-urging-support-for-proposed-merger-with-pharma-two-b\/","name":"Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hepion-pharmaceuticals-issues-letter-to-shareholders-urging-support-for-proposed-merger-with-pharma-two-b\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hepion-pharmaceuticals-issues-letter-to-shareholders-urging-support-for-proposed-merger-with-pharma-two-b\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI5MTA4MiM2NjEzOTkxIzUwMDEyMDY2Ng==","datePublished":"2024-12-02T13:18:38+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hepion-pharmaceuticals-issues-letter-to-shareholders-urging-support-for-proposed-merger-with-pharma-two-b\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/hepion-pharmaceuticals-issues-letter-to-shareholders-urging-support-for-proposed-merger-with-pharma-two-b\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hepion-pharmaceuticals-issues-letter-to-shareholders-urging-support-for-proposed-merger-with-pharma-two-b\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI5MTA4MiM2NjEzOTkxIzUwMDEyMDY2Ng==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI5MTA4MiM2NjEzOTkxIzUwMDEyMDY2Ng=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hepion-pharmaceuticals-issues-letter-to-shareholders-urging-support-for-proposed-merger-with-pharma-two-b\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/791491","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=791491"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/791491\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=791491"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=791491"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=791491"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}